Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. sends Brazil 2 million doses of hydroxychloroquine, drug touted by Trump

Published 05/31/2020, 05:36 PM
Updated 05/31/2020, 05:40 PM
© Reuters. FILE PHOTO: The drug hydroxychloroquine, pushed by U.S. President Donald Trump and others in recent months as a possible treatment to people infected with the coronavirus disease (COVID-19), is displayed by a pharmacist in Provo

By Matt Spetalnick

WASHINGTON (Reuters) - The United States has supplied Brazil with 2 million doses of hydroxychloroquine for use against the coronavirus, the two governments said on Sunday, despite medical warnings about risks associated with the anti-malaria drug.

The White House released a joint announcement on the drug, whose use has been touted both by U.S. President Donald Trump and Brazilian President Jair Bolsonaro, just days after the World Health Organization suspended testing it in COVID-19 patients because of safety concerns.

Trump himself said in mid-May that he was on a regimen of hydroxychloroquine as a preventive measure, even though the U.S. Food and Drug Administration had issued a warning about its use for the coronavirus.

Bolsonaro, a right-wing leader who has forged personal ties with Trump, said recently he kept a box of the drug in case his 93-year-old mother needed it.

"The American and Brazilian people stand in solidarity in the fight against the coronavirus,” the statement said. “We are announcing the United States Government has delivered two million doses of hydroxychloroquine (HCQ) to the people of Brazil.”

“HCQ will be used as a prophylactic to help defend Brazil’s nurses, doctors and healthcare professionals against the virus. It will also be used as a therapeutic to treat Brazilians who become infected,” it said.

The two countries will also conduct a joint research effort that will include “randomized controlled clinical trials,” the statement said, adding that the United States would soon send 1,000 ventilators to Brazil.

Brazil reported a record 33,274 new cases of the novel coronavirus on Saturday, its Health Ministry said, and the death toll surpassed that of France and now ranks only below the United States, Britain and Italy.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Demand for the decades-old hydroxychloroquine has surged as Trump repeatedly promoted its use against the coronavirus despite a lack of scientific evidence.

Latest comments

Brazil listen up! you've got the goodies. now it's time for you to send your hot chicks here.
Maybe we can sent some injectable LySol or bleach as well????
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.